EpiBiologics
Develops bispecific antibodies for targeted degradation of extracellular proteins.
$107MSeries B
Role not disclosedNV
Novartis Venture Fund (NVF)
Activity from announced rounds
Activity in this selectionfuture-back-ventures-by-bain-company-8be8de73
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $107M 1 disclosed · full round size, not this investor’s share